Could a common gout drug save hearts? colchicine trial targets valve disease
NCT ID NCT05162742
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This phase 3 trial tests whether colchicine, an anti-inflammatory drug, can slow the progression of aortic valve stenosis—a narrowing of the heart's aortic valve that currently has no drug treatment. The study enrolls 150 people with moderate, symptom-free valve disease. Participants receive either colchicine or a placebo for up to 2 years, and researchers track changes in valve calcium buildup and other measures. If successful, colchicine could become the first medical therapy for this condition.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
colchicine
What this could lead to
If it works, this could be the first drug to slow aortic valve stenosis, potentially delaying or avoiding the need for valve replacement surgery.
What could go wrong
This is a relatively small phase 3 trial (150 people) testing a drug already used for other conditions. The effect may be modest or not significant, and colchicine can cause side effects like stomach upset.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for INFLAMMATION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Radboudumc
Nijmegen, The Netherlands, Netherlands